Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 925-929

  Xu, Rong ^a   Ma, Nan ^a   Wang, Fang ^a   Ma, Lei ^a   Chen, Rui ^a   Chen, Ru ^a   Kebinu, Mijiti ^a   Ma, Lili ^a   Han, Zhongcheng ^a   Ayixiamu, ^a   Mayier, Mahemiti ^a   Su, Pengcheng ^a   Naman, Yiming ^a   Jieensi, Haliyazimu ^a   Yang, Haixuan ^a   Adili, Abulizi ^a   Aili, Saiding ^a   Liu, Jiang ^a  

^a Peoples Hospital of Xinjiang Municipality   (China)

Author keywords

Endostar; Endostatin; Gastric cancer; Oxaliplatin; S 1; SOX

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; RECOMBINANT ENDOSTATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PIGMENT DISORDER; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TOXIC HEPATITIS; VOMITING;

EID: 84880975350     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S46487     Document Type: Article

References (23)

1. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37-41.
2. Glimelius B, Hoffman K, Haglund U, Nyrén O, Sjödén PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994;5:189-190.
3. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer. 1995;71:587-591.
4. Gao SG, Jia RN, Feng XS, et al. Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma. World J Gastroenterol. 2011;17:5221-5226.
5. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-1820.
6. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
7. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-1442.
8. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012;48:518-526.
9. Oh SY, Kwon HC, Jeong SH, et al. A phase II study of S-1 and oxaliplatin (SOX) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs. 2012;30:350-356.
10. Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2010;21:1001-1005.
11. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-18.
12. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
13. Zhuang HQ, Yuan ZY. Process in the mechanisms of endostatin combined with radiotherapy. Cancer Lett. 2009;282:9-13.
14. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res. 2006;312:594-607.
15. Grosios K. Endostatin (EntreMed). IDrugs. 2000;3:799-810.
16. Wang J, Sun Y, Liu Y. Results of randomised, multicentre, doubleblind phase III trial of rh-endostantin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer. 2005;8: 283-290.
17. Ke QH, Zhou SQ, Huang M, Lei Y, Du W, Yang JY. Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers. Asian Pac J Cancer Prev. 2012;13:923-926.
18. Zhou JF, Bai CM, Wang YZ, Li XY, Cheng YJ, Chen SC. Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study. Chin Med J (Engl). 2011;124: 4299-4303.
19. Zhou ZT, Zhou FX, Wei Q, Zou LY, Qin BF, Peng XS. Phase II study of cisplatin/etoposide and Endostar for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol. 2011;68:1027-1032.
20. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354-362.
21. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;28:687-697.
22. Sato A, Ito T, Tomita T, Nakamura A, Taguchi S. Chemotherapy of gastric cancer - a review of clinical trials in Japan. Gan To Kagaku Ryoho. 2002;29:1522-1531. Japanese.
23. Ling Y, Yang Y, Lu N, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007;361:79-84.